Abstract
Immune tolerance-inducing therapies reprogramme immune cells to eliminate pathogenic immune responses while preserving protective immunity. The Immune Tolerance Network (ITN), sponsored by the US National Institutes of Health, was established in 1999 to evaluate new tolerance-inducing therapies and carry out mechanistic studies using a unique interactive approach in partnership with industry, academia and foundations. Ten years later, the ITN has carried out approximately 36 clinical trials and tolerance studies examining innovative tolerogenic approaches in the settings of allergy, autoimmune diseases and organ transplantation. ITN investigators have published more than 80 original research papers based on this work. This Timeline article summarizes the progress and challenges of clinical research in the ITN.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Girlanda, R. & Kirk, A. D. Frontiers in nephrology: immune tolerance to allografts in humans. J. Am. Soc. Nephrol. 18, 2242–2251 (2007).
Lenschow, D. J. & Bluestone, J. A. T cell co-stimulation and in vivo tolerance. Curr. Opin. Immunol. 5, 747–752 (1993).
Durham, S. R. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341, 468–475 (1999).
Bluestone, J. A. & Matthews, J. B. The immune tolerance network — an NIH/JDF-supported initiative to bring tolerance research into the clinic: a major new resource for clinical immunologists. Clin. Immunol. 96, 171–173 (2000).
Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698 (2002).
Herold, K. C. et al. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 132, 166–173 (2009).
Utset, T. O. et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. 29, 1907–1913 (2002).
You, S. et al. Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl Acad. Sci. USA 104, 6335–6340 (2007).
Morelon, E. et al. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. Transpl. Immunol. 23, 53–58 (2010).
Rothstein, D. M. & Sayegh, M. H. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. Rev. 196, 85–108 (2003).
Sidiropoulos, P. I. & Boumpas, D. T. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13, 391–397 (2004).
Viglietta, V. et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 71, 917–924 (2008).
Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687–697 (2008).
Rabinovitch, A., Suarez-Pinzon, W. L., Shapiro, A. M., Rajotte, R. V. & Power, R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 51, 638–645 (2002).
Battaglia, M. et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177, 8338–8347 (2006).
Weaver, T. A. et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nature Med. 15, 746–749 (2009).
Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).
Youssef, S. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a TH2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78–84 (2002).
Waubant, E. et al. Atorvastatin therapy in patients with clinically isolated syndrome and high-risk for conversion to multiple sclerosis: the STAyCIS study. Multiple Sclerosis 15, S271–S277 (2009).
Louvet, C. et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc. Natl Acad. Sci. USA 105, 18895–18900 (2008).
Koulmanda, M. et al. Curative and beta cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl Acad. Sci. USA 105, 16242–16247 (2008).
Valentine, M. D. et al. The value of immunotherapy with venom in children with allergy to insect stings. N. Engl. J. Med. 323, 1601–1603 (1990).
Casale, T. B. et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 117, 134–140 (2006).
Creticos, P. S. et al. Immunotherapy with a ragweed–Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355, 1445–1455 (2006).
Billingham, R. E., Brent, L. & Medawar, P. B. Actively acquired tolerance of foreign cells. Nature 172, 603–606 (1953).
Du Toit, G. et al. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J. Allergy Clin. Immunol. 122, 984–991 (2008).
Kawai, T. et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358, 353–361 (2008).
Fudaba, Y. et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant. 6, 2121–2133 (2006).
Knechtle, S. J. et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am. J. Transplant. 9, 1087–1098 (2009).
Feng, S. et al. ITN029ST: Immunosuppression withdrawal in pediatric recipients of parental living donor liver transplants: preliminary results of a pilot study. Abstract No. 189 (American Transplant Congress, Boston, Massachusetts, 2009).
Newell, K. A. et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120, 1836–1847 (2010).
Sagoo, P. et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 120, 1848–1861 (2010).
Sanchez-Fueyo, A. Identification of tolerant recipients following liver transplantation. Int. Immunopharmacol. 29 Jun 2010 (doi: 10.1016/j.intimp.2010.06.011).
Gebauer, B. S. et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am. J. Transplant. 2, 857–866 (2002).
Ding, R. et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation 75, 1307–1312 (2003).
Mazariegos, G. V. et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am. J. Transplant. 3, 689–696 (2003).
Muthukumar, T. et al. Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation 75, 1565–1570 (2003).
Reijonen, H. & Kwok, W. W. Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T-cell epitopes. Methods 29, 282–288 (2003).
Yang, J., Jaramillo, A., Shi, R., Kwok, W. W. & Mohanakumar, T. In vivo biotinylation of the major histo-compatibility complex (MHC) class II/peptide complex by co-expression of BirA enzyme for the generation of MHC class II/tetramers. Hum. Immunol. 65, 692–699 (2004).
Seyfert-Margolis, V. et al. Analysis of T cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 55, 2588–2594 (2006).
Shamji, M. H. et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based assay for the detection of inhibitory antibody responses. J. Immunol. Methods 317, 71–79 (2006).
Shapiro, A. M. J. et al. International multicenter trial of islet transplantation with the Edmonton protocol in type 1 diabetes. N. Engl. J. Med. 355, 1318–1330 (2006).
Klunker, S. et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J. Allergy Clin. Immunol. 120, 688–695 (2007).
Zhang, L. et al. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin. Immunol. 125, 131–137 (2007).
Porcheray, F. et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am. J. Transplant. 9, 2126–2135 (2009).
Acknowledgements
We thank the many people inside the ITN, NIAID and Rho, as well as the immunology community at large, for the hard work, support and creative ideas that have helped the ITN to flourish. Special thanks to the ITN funders — NIAID, JDRF, FAI and NIDDK — and to all the companies who have worked with the ITN and its clinical investigators.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Jeffrey A. Bluestone, Hugh Auchincloss, Gerald T. Nepom, Daniel Rotrosen, E. William St. Clair and Laurence A. Turka The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nature Reviews Immunology 10, 797–803 (2010); doi:10.1038/nri2869
Jeffrey A. Bluestone has a financial interest in MacroGenics both as a stockholder and as a paid consultant.
Rights and permissions
About this article
Cite this article
Bluestone, J., Auchincloss, H., Nepom, G. et al. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol 10, 797–803 (2010). https://doi.org/10.1038/nri2869
Published:
Issue Date:
DOI: https://doi.org/10.1038/nri2869
This article is cited by
-
Two heads are better than one: current landscape of integrating QSP and machine learning
Journal of Pharmacokinetics and Pharmacodynamics (2022)
-
Long-term tolerance of islet allografts in nonhuman primates induced by apoptotic donor leukocytes
Nature Communications (2019)
-
Genetic interaction between two insulin-dependent diabetes susceptibility loci, Idd2 and Idd13, in determining immunoregulatory DN T cell proportion
Immunogenetics (2018)
-
Hope vs hype: where are we in type 1 diabetes?
Diabetologia (2018)
-
Uterine Tissue Engineering and the Future of Uterus Transplantation
Annals of Biomedical Engineering (2017)